Skip to main content
Top
Published in: Hereditary Cancer in Clinical Practice 1/2016

Open Access 01-12-2016 | Case report

Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer

Authors: Matilde Pensabene, Caterina Condello, Chiara Carlomagno, Sabino De Placido, Raffaella Liccardo, Francesca Duraturo

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2016

Login to get access

Abstract

Background

Early-onset or hereditary ovarian cancer is mostly associated with BRCA1 or BRCA2 mutations. Mismatch repair genes sequence alteration frequently cause colorectal cancer, and, in less extent, other tumors, such as ovarian cancer. Subjects with personal and/or family history suggestive for hereditary cancer should be addressed to cancer genetic counseling, aimed to the identification, definition and management of hereditary cancer syndrome, by a multidisciplinary approach.

Case presentation

A woman with a very early onset epithelial ovarian cancer underwent to cancer genetic counseling and genetic testing. Pedigree analysis suggested a clinical diagnosis of Lynch II syndrome, according to the Amsterdam criteria. The MMRpro model showed a cumulative risk of mutation of 50.3 %, thus, genetic testing was offered to the patient. Two germ-line mutations have been identified in exon 11 of MSH2 gene: c.1706A > T (p.Glu569Val) and c.1711G > T (p.Glu571*). Both DNA alterations were novel mutations not yet described in literature. The first is a missense mutation that is to be considered an unclassified variant; the second is nonsense mutation that created a premature stop codon resulting in a truncated not functioning protein. Both genetic alterations were found in the patients’ father DNA.

Conclusions

The present report finds out two unpublished sequence alterations in exon 11 of the MSH2 gene, one on which can be considered causative of Lynch phenotype. Moreover, it stresses the importance of the multidisciplinary onco-genetic counselling in order to correctly frame the hereditary syndrome, suggest the right genetic test, and offer the most appropriate management of the cancer risk for the patients and her family members.
Literature
2.
go back to reference Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;10:80–7. doi:10.1093/jnci/djn442.CrossRef Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;10:80–7. doi:10.​1093/​jnci/​djn442.CrossRef
5.
go back to reference Duraturo F, Cavallo A, Liccardo R et al. Contribution of large genomic rearrangements in Italian Lynch syndrome patients: characterization of a novel alu-mediated deletion. Biomed Res Int. 2013:219897. doi: 10.1155/2013/219897. Duraturo F, Cavallo A, Liccardo R et al. Contribution of large genomic rearrangements in Italian Lynch syndrome patients: characterization of a novel alu-mediated deletion. Biomed Res Int. 2013:219897. doi: 10.​1155/​2013/​219897.
6.
go back to reference Contegiacomo A, Pensabene M, Capuano I, on behalf of the Italian Network on Hereditary Breast Cancer, et al. An oncologist-based model of cancer genetic counseling for hereditary breast and ovarian cancer. Ann Oncol. 2004;15:726–32.CrossRefPubMed Contegiacomo A, Pensabene M, Capuano I, on behalf of the Italian Network on Hereditary Breast Cancer, et al. An oncologist-based model of cancer genetic counseling for hereditary breast and ovarian cancer. Ann Oncol. 2004;15:726–32.CrossRefPubMed
7.
go back to reference Riley BD, Culver JO, Skrzynia C, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns. 2012;21:151–61. doi:10.1007/s10897-011-9462-x.CrossRefPubMed Riley BD, Culver JO, Skrzynia C, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns. 2012;21:151–61. doi:10.​1007/​s10897-011-9462-x.CrossRefPubMed
8.
go back to reference Condello C, Gesuita R, Pensabene M, et al. Distress and family functioning in oncogenetic counselling for hereditary and familial breast and/or ovarian cancers. J Genet Couns. 2007;16:625–34.CrossRefPubMed Condello C, Gesuita R, Pensabene M, et al. Distress and family functioning in oncogenetic counselling for hereditary and familial breast and/or ovarian cancers. J Genet Couns. 2007;16:625–34.CrossRefPubMed
10.
go back to reference Costantini M, Musso M, Viterbori P, et al. Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer. 1999;7:121–7.CrossRefPubMed Costantini M, Musso M, Viterbori P, et al. Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer. 1999;7:121–7.CrossRefPubMed
12.
go back to reference Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.CrossRefPubMedPubMedCentral Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.CrossRefPubMedPubMedCentral
13.
go back to reference Duraturo F, Liccardo R, Cavallo A, et al. Multivariate analysis as a method for evaluating the pathogenicity of novel genetic MLH1 variants in patients with colorectal cancer and microsatellite instability. Int J Mol Med. 2015;36(2):511–7.PubMed Duraturo F, Liccardo R, Cavallo A, et al. Multivariate analysis as a method for evaluating the pathogenicity of novel genetic MLH1 variants in patients with colorectal cancer and microsatellite instability. Int J Mol Med. 2015;36(2):511–7.PubMed
14.
go back to reference De Rosa M, Morelli G, Cesaro E, et al. Alternative splicing and nonsense-mediated mRNA decay in the regulation of a new adenomatous polyposis coli transcript. Gene. 2007;395:8–14.CrossRefPubMed De Rosa M, Morelli G, Cesaro E, et al. Alternative splicing and nonsense-mediated mRNA decay in the regulation of a new adenomatous polyposis coli transcript. Gene. 2007;395:8–14.CrossRefPubMed
15.
go back to reference Houlle S, Charbonnier F, Houivet E, et al. Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers. Eur J Hum Genet. 2011;19:887–92.CrossRefPubMedPubMedCentral Houlle S, Charbonnier F, Houivet E, et al. Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers. Eur J Hum Genet. 2011;19:887–92.CrossRefPubMedPubMedCentral
16.
go back to reference Meiser B. Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psychooncology. 2005;14:1060–74.CrossRefPubMed Meiser B. Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psychooncology. 2005;14:1060–74.CrossRefPubMed
Metadata
Title
Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer
Authors
Matilde Pensabene
Caterina Condello
Chiara Carlomagno
Sabino De Placido
Raffaella Liccardo
Francesca Duraturo
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2016
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/s13053-016-0054-5

Other articles of this Issue 1/2016

Hereditary Cancer in Clinical Practice 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine